This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Understanding pharmacy benefit management and drugpricing The U.S. prescription drug supply chain is extraordinarily complex. It captures, with strong simplification, the web of stakeholders in the prescription drug market and the myriad of contractual agreements that drives the cash flows between them.
Vanda Pharmaceuticals, Inc. Under the Medicaid Drug Rebate statute, a pharmaceuticalmanufacturer whose drugprices increase faster than the rate of inflation must pay additional per-unit rebates to the program. We previously blogged on the district court’s decision last year. 23-1457 (4th Cir.
Gaulkin — Enacted in 2022, the Inflation Reduction Act (IRA) amended the Medicare provisions of the Social Security Act to impose several discount requirements on pharmaceuticalmanufacturers.
By Faraz Siddiqui — Last week, a federal court in Ohio denied a preliminary injunction motion by four Chambers of Commerce in their lawsuit against the Medicare DrugPrice Negotiation Program. Standing The Defendants questioned, and the court reviewed, Plaintiffs’ standing.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content